Cargando…

Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin

Drug transporter and cytochrome P450 expression is regulated by shared nuclear receptors and, hence, an inducer should induce both, although the magnitude may differ. The objective of this study was to establish relative induction relationships between CYP3A and drug transporters (P‐glycoprotein (P‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Lutz, Justin D., Kirby, Brian J., Wang, Lu, Song, Qinghua, Ling, John, Massetto, Benedetta, Worth, Angela, Kearney, Brian P., Mathias, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282691/
https://www.ncbi.nlm.nih.gov/pubmed/29569723
http://dx.doi.org/10.1002/cpt.1073
_version_ 1783379048045477888
author Lutz, Justin D.
Kirby, Brian J.
Wang, Lu
Song, Qinghua
Ling, John
Massetto, Benedetta
Worth, Angela
Kearney, Brian P.
Mathias, Anita
author_facet Lutz, Justin D.
Kirby, Brian J.
Wang, Lu
Song, Qinghua
Ling, John
Massetto, Benedetta
Worth, Angela
Kearney, Brian P.
Mathias, Anita
author_sort Lutz, Justin D.
collection PubMed
description Drug transporter and cytochrome P450 expression is regulated by shared nuclear receptors and, hence, an inducer should induce both, although the magnitude may differ. The objective of this study was to establish relative induction relationships between CYP3A and drug transporters (P‐glycoprotein (P‐gp), organic anion transporting polypeptide (OATP), and breast cancer resistance protein (BCRP)) or other P450s (CYP2C9 and CYP1A2) using ascending doses of the prototypical pregnane xenobiotic receptor (PXR) agonist, rifampin, to elicit weak, moderate, and strong PXR agonism. Healthy subjects received dabigatran etexilate, pravastatin, rosuvastatin, and a midazolam/tolbutamide/caffeine cocktail before and after rifampin 2, 10, 75, or 600 mg q.d. Unlike CYP3A, only moderate induction of P‐gp, OATP, and CYP2C9 was observed and dose‐dependent induction of P‐gp, OATP, and CYP2C9 was always one drug–drug interaction category lower than observed for CYP3A, even when correcting for probe drug sensitivity. Data from this study establish proof‐of‐concept that P450 induction data can be leveraged to inform on the effect on transporters.
format Online
Article
Text
id pubmed-6282691
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62826912018-12-10 Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin Lutz, Justin D. Kirby, Brian J. Wang, Lu Song, Qinghua Ling, John Massetto, Benedetta Worth, Angela Kearney, Brian P. Mathias, Anita Clin Pharmacol Ther Research Drug transporter and cytochrome P450 expression is regulated by shared nuclear receptors and, hence, an inducer should induce both, although the magnitude may differ. The objective of this study was to establish relative induction relationships between CYP3A and drug transporters (P‐glycoprotein (P‐gp), organic anion transporting polypeptide (OATP), and breast cancer resistance protein (BCRP)) or other P450s (CYP2C9 and CYP1A2) using ascending doses of the prototypical pregnane xenobiotic receptor (PXR) agonist, rifampin, to elicit weak, moderate, and strong PXR agonism. Healthy subjects received dabigatran etexilate, pravastatin, rosuvastatin, and a midazolam/tolbutamide/caffeine cocktail before and after rifampin 2, 10, 75, or 600 mg q.d. Unlike CYP3A, only moderate induction of P‐gp, OATP, and CYP2C9 was observed and dose‐dependent induction of P‐gp, OATP, and CYP2C9 was always one drug–drug interaction category lower than observed for CYP3A, even when correcting for probe drug sensitivity. Data from this study establish proof‐of‐concept that P450 induction data can be leveraged to inform on the effect on transporters. John Wiley and Sons Inc. 2018-04-19 2018-12 /pmc/articles/PMC6282691/ /pubmed/29569723 http://dx.doi.org/10.1002/cpt.1073 Text en © 2018 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Lutz, Justin D.
Kirby, Brian J.
Wang, Lu
Song, Qinghua
Ling, John
Massetto, Benedetta
Worth, Angela
Kearney, Brian P.
Mathias, Anita
Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin
title Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin
title_full Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin
title_fullStr Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin
title_full_unstemmed Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin
title_short Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin
title_sort cytochrome p450 3a induction predicts p‐glycoprotein induction; part 1: establishing induction relationships using ascending dose rifampin
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282691/
https://www.ncbi.nlm.nih.gov/pubmed/29569723
http://dx.doi.org/10.1002/cpt.1073
work_keys_str_mv AT lutzjustind cytochromep4503ainductionpredictspglycoproteininductionpart1establishinginductionrelationshipsusingascendingdoserifampin
AT kirbybrianj cytochromep4503ainductionpredictspglycoproteininductionpart1establishinginductionrelationshipsusingascendingdoserifampin
AT wanglu cytochromep4503ainductionpredictspglycoproteininductionpart1establishinginductionrelationshipsusingascendingdoserifampin
AT songqinghua cytochromep4503ainductionpredictspglycoproteininductionpart1establishinginductionrelationshipsusingascendingdoserifampin
AT lingjohn cytochromep4503ainductionpredictspglycoproteininductionpart1establishinginductionrelationshipsusingascendingdoserifampin
AT massettobenedetta cytochromep4503ainductionpredictspglycoproteininductionpart1establishinginductionrelationshipsusingascendingdoserifampin
AT worthangela cytochromep4503ainductionpredictspglycoproteininductionpart1establishinginductionrelationshipsusingascendingdoserifampin
AT kearneybrianp cytochromep4503ainductionpredictspglycoproteininductionpart1establishinginductionrelationshipsusingascendingdoserifampin
AT mathiasanita cytochromep4503ainductionpredictspglycoproteininductionpart1establishinginductionrelationshipsusingascendingdoserifampin